KPIs & Operating Metrics(New)
Biopharma Testing VolumeBreakdown Of AssetsClinical VolumeContractual ObligationsCost Of RevenueCost Of Revenue By SegmentDeferred RevenueEmployee StatisticsGross Margin %Gross Margin By Segment %Gross ProfitGross Profit By SegmentIncome Before Provision For Income TaxesNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Opex As A % Of RevenueOPEX BreakdownProperty And Equipment, NetRevenueRevenue By RegionRevenue By Region %Revenue By Region AnnualRevenue By Region Annual %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Guardant Health (GH) Cost Of Revenue (2025)

Guardant Health's Cost of Revenue history spans 9 years, with the latest figure at -$2.3 million for Q4 2025.

  • For Q4 2025, Cost of Revenue fell 102.17% year-over-year to -$2.3 million; the TTM value through Dec 2025 reached $349.0 million, down 4.36%, while the annual FY2025 figure was $349.0 million, 4.36% down from the prior year.
  • Cost of Revenue for Q4 2025 was -$2.3 million at Guardant Health, down from $127.4 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $127.4 million in Q3 2025 and bottomed at -$218.4 million in Q4 2022.
  • The 5-year median for Cost of Revenue is $74.9 million (2022), against an average of $50.5 million.
  • The largest annual shift saw Cost of Revenue plummeted 522.79% in 2021 before it skyrocketed 136.23% in 2023.
  • A 5-year view of Cost of Revenue shows it stood at -$132.3 million in 2021, then plummeted by 65.11% to -$218.4 million in 2022, then soared by 136.23% to $79.1 million in 2023, then soared by 32.4% to $104.8 million in 2024, then crashed by 102.17% to -$2.3 million in 2025.
  • Per Business Quant, the three most recent readings for GH's Cost of Revenue are -$2.3 million (Q4 2025), $127.4 million (Q3 2025), and $119.6 million (Q2 2025).